替吉奥单药或联合铂类治疗晚期非小细胞肺癌患者疗效与安全性的Meta评价

林莉莉; 黄爱文; 林美钦; 方婕; 沈钦勇; 宋洪涛; 林莉莉; 黄爱文; 林美钦; 方婕; 沈钦勇; 宋洪涛

doi:10.3969/j.issn.1006-0111.2019.06.018

[1]

CRONIN K A,LAKE A J,SCOTT S,et al.Annual report to the nation on the status of cancer,part I:National cancer statistics[J].Cancer,2018,124(13):2785-2800.

[2]

SAKURADA T,KAKIUCHI S,TAJIMA S,et al.Characteristics of and risk factors for interstitial lung disease induced by chemotherapy for lung cancer[J].Ann Pharmacother,2015,49(4):398-404.

[3]

余佳文,王增,程斌.替吉奥联合化疗治疗中晚期非小细胞肺癌的疗效和安全性的Meta分析[J].中国药房,2014,25(20):1897-1900.

[4]

YOSHIOKA H,OKAMOTO I,MORITA S,et al.Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer:updated results of the West Japan Oncology Group LETS study[J].Ann Oncol,2013,24(5):1326-1331.

[5]

OKAMOTO I,YOSHIOKA H,MORITA S,et al.Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-na?ve patients with advanced non-small-cell lung cancer:results of a west Japan oncology group study[J].J Clin Oncol,2010,28(36):5240-5246.

[6]

陈婵娟,陈昌南,林云笑,等.替吉奥与紫杉醇联合铂类治疗老年中晚期非小细胞肺癌的临床对比分析[J].赣南医学院学报,2015,35(1):73-75.

[7]

龙燕.替吉奥或紫杉醇联合顺铂治疗中晚期非小细胞肺癌的疗效比较[J].广东医学院学报, 2016,34(6):632-634.

[8]

王继贤.紫杉醇脂联合顺铂与替吉奥联合顺铂在晚期非小细胞肺癌患者中的应用效果对比[J].癌症进展,2016,14(3):272-273.

[9]

徐继业.紫杉醇联合顺铂与替吉奥联合顺铂治疗中晚期肺癌的对比分析[J].实用癌症杂志, 2016,31(10):1631-1633.

[10]

柳宝,陈公琰.替吉奥与多西他赛分别联合顺铂一线治疗晚期非小细胞肺癌的临床观察[J].中国肿瘤临床与康复,2013,20(7):734-736.

[11]

潘永军,沈广洪,邹晓瑜,等.替吉奥二线治疗老年晚期非小细胞肺癌疗效分析[J].中国肿瘤外科杂志,2015,7(5):312-314.

[12]

NISHINO K,IMAMURA F,KUMAGAI T,et al.A randomized phase II study of bevacizumab in combination with docetaxel or S-1 in patients with non-squamous non-small-cell lung cancer previously treated with platinum based chemotherapy (HANSHIN Oncology Group 0110)[J].Lung Cancer,2015,89(2):146-153.

[13]

KUBOTA K,SAKAI H,KATAKAMI N,et al.A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer:TCOG0701 CATS trial[J].Ann Oncol,2015,26(7):1401-1408.

[14]

王雨.探讨替吉奥与多西他赛单药方案一线治疗高龄晚期非小细胞肺癌的疗效分析[J].中国医药指南,2016,14(27):83-83.

[15]

郭依龙,周恒根,倪敬中.替吉奥或多西他赛联合铂类治疗老年中晚期非小细胞肺癌的疗效和安全性[J].实用医学杂志,2016,32(22):3782-3784.

[16]

NOKIHARA H,LU S,MOK T S K,et al.Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer)[J].Ann ?癮楣獯瑬愬猲嬰?崷??瀸渨????氲椶渹?伭渲挷漰氶?监ぢひ?????ㄠ??水????贺文茜,等.替吉奥联合顺铂与吉西他滨联合顺铂治疗晚期非小细胞肺癌的疗效对比观察[J].中国老年保健医学,2012,10(4):101-103.

[17]

刘萍.替吉奥维持治疗晚期非小细胞肺癌临床疗效观察[J].中国全科医学,2013,16(11):1038-1040.

[18]

石彧,王志祥.替吉奥维持治疗晚期非小细胞肺癌的临床疗效观察[J].中国医药指南,2014,12(4):169-170.

[19]

孔静,张一桥.替吉奥联合顺铂治疗晚期非小细胞肺癌的临床疗效[J].中国肿瘤临床与康复.2014,21(12):1455-1458.

[20]

孙成晖,吴国强,严伟红,等.替吉奥和吉西他滨分别联合顺铂一线治疗EGFR野生型的晚期非小细胞肺癌的临床观察[J].中国医院药学杂志,2015,35(23):2129-2132.

[21]

王碧荣,李卫东,邓旭斌,等.替吉奥维持治疗EGFR野生型晚期非小细胞肺癌临床观察[J].中国现代医生,2016,54(19):87-90.

[22]

史磊,张国耀,马天江.替吉奥与吉西他滨分别联合顺铂一线治疗Ⅳ期非小细胞肺癌的临床观察[J].中国实用医药,2016,11(15):164-165.

[23]

陈巧霞.吉西他滨与替吉奥在老年中晚期非小细胞肺癌治疗中的对比研究[J].医药论坛杂志,2017,38(5):134-136.

[24]

施湘萍.替吉奥或吉西他滨联合顺铂一线治疗EGFR野生型晚期非小细胞肺癌40例临床评价[J].中国药业,2017,26(22):52-54.

[25]

钱滨滨.替吉奥与吉西他滨分别联合顺铂治疗EGFR野生型肺癌研究[J].中国继续医学教育,2017,9(31):106-108.

[26]

李景,周彩云,宋敏,等.探讨替吉奥胶囊单药治疗老年晚期非小细胞肺癌的临床效果[J].中国现代药物应用,2018,12(21):85-86.

[27]

陈伟.替吉奥和吉西他滨分别联合顺铂治疗晚期非小细胞肺癌的临床观察[J].中国医药指南,2018,16(6):5-6.

[28]

YE T,PAN Y J,WANG R,et al.Analysis of the molecular and clinicopathologic features of surgically resected lung adenocarcinoma in patients under 40 years old[J].J Thorac Dis,2014,6(10):1396-1402.

[29]

SCHILLER J H,HARRINGTON D,BELANI C P,et al.Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer[J].N Engl J Med,2002,346(2):92-98.

[30]

ICHINOSE Y,YOSHIMORI K,SAKAI H,et al.S-1 plus cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer:A multi-institutional phase II trial[J].Clin Cancer Res,2004,10(23):7860-7864.

[31]

DI MAIO M,PERRONE F,CHIODINI P,et al.Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer[J].J Clin Oncol,2007,25(11):1377-1382.

[32]

JAPANESE GASTRIC CANCER ASSOCIATION.Japanese gastric cancer treatment guidelines 2014(ver.4)[J].Gastric Cancer,2017,20(1):1-19.

[33]

SHIRASAKA T.Development history and concept of an oral anticancer agent S-1(TS-1):its clinical usefulness and future